Clinical Trial Update: Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration [Phase 3]

View source ↗

Summary

Phase 3 trial comparing biosimilar ranibizumab FYB201 to Lucentis in neovascular age-related macular degeneration completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• FYB201 (ranibizumab biosimilar)
• Lucentis (ranibizumab)

Snippet

Sponsor: Bioeq GmbH | Conditions: Age-related Macular Degeneration (AMD) | Phase 3 | Status: COMPLETED | Results posted: 2021-09-30